Al-Ola A Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared a post on X:
“Stopping early-relapse myeloma calls for an elite combo.
Teclistamab plus Daratumumab — a duo as tough as Maldini plus Cannavaro shutting down the Fenomeno!
Soon to be approved!”
More posts about Myeloma.